Revolution Medicines, Inc., a clinical-stage precision oncology company, is revolutionizing cancer treatment through its innovative therapies designed to obstruct frontier targets in RAS-addicted cancers. At the forefront of Revolution Medicines' portfolio is RMC-4630, a promising inhibitor of SHP2, currently in Phase 1/2 clinical trials for the treatment of solid tumors, including gynecologic tumors. In addition to RMC-4630, the biotech firm is also developing RMC-5845, targeted at inhibiting SOS1, a protein that triggers the conversion of RAS (OFF) to RAS (ON) in cells, and RMC-5552, an exclusive inhibitor of mTORC1 signaling in tumors. Moreover, the company is advancing the development of RMC-6291 and RMC-6236, both significant inhibitors of KRASG12C(ON) and multiple RAS(ON) variants, respectively, and RAS(ON) inhibitors designed to target KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. recently sealed a significant partnership in its research and development of SHP2 inhibitors, including RMC-4630, with multinational pharmaceutical company Sanofi. Headquartered in Redwood City, California, the biotech company was established in 2014 and is poised to revolutionize the clinical landscape of cancer treatment.